Go to the main content

Department of Medicine
Clinical Collaboration Unit Translational Immunology

500
501
502
503
560

Address: Otfried-Müller-Str. 10
72076 Tübingen


Administration Office

frontend.sr-only_#{element.icon}: +49 7071 29-83275


frontend.sr-only_#{element.icon}: +49 7071 29-4391


frontend.sr-only_#{element.icon}: Sabrina.augstein@med.uni-tuebingen.de


About us

The Clinical Cooperation Unit Translational Immunology is a multidisciplinary unit that develops and applies novel immunotherapeutics for cancer patients. It draws on experience obtained in decades of research regarding the development of optimized antitumor antibodies and vaccination strategies, combined with our expertise in the treatment of malignant diseases and the clinical evaluation of new therapeutic concepts. We work closely together with the specialists at the other Departments at University Hospital Tübingen that treat cancer patients as well as the Department of Immunology.

Direction

Prof. Dr. med. Helmut Salih

Medical director

Office:

Phone number: +49 7071 29-83275

Fax number: +49 7071 29-4391

E-mail address: Sabrina.augstein@med.uni-tuebingen.de

Person profile: More about the person

PD Dr. med. Juliane Walz

Consultant

Person profile: More about the person

Clinical studies

COR-101
First-in-human study to evaluate the safety, tolerability and efficacy of the Fc-modified antibody COR-101 in patients with moderate to severe COVID-19 disease.

Synopsis

Information about the study

FLYSYN-101

First in man study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease.

Synopsis

iVAC-CLL01

Patient-individualized peptide vaccination after first line therapy of CLL

iVAC-XS15-CLL01

Personalized peptide vaccination in combination with the TLR2 ligand XS15 for CLL patients under ibrutinib treatment. 

Synopsis

DKTK_PMO_1605

First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma

Start of recruitment planned Q4/2019

Synopsis


Patient individual immunotherapy concepts

The direct link between research and patient care enables us to offer our patients newly developed and personalized immunotherapic concepts for tumor diseases.

Appointments

Please note that for enquiries regarding participation in our clinical trials or for medical consulation on cancer immunotherapy concepts, it is mandatory that the treating physician beforehand provides your treatment documents (current doctor's letter, imaging findings, etc.), ideally via e-mail:

E-mail address: KKETI@med.uni-tuebingen.de


Office for clinical studies:

Sabrina Sauter
Hannah Zug
Janine Nebel

+49 7071 29-82834


News

1. December 2020

Novel vaccine trial to activate T-cell responses against SARS-CoV-2

University Hospital Tübingen starts clinical studies with an in-house developed vaccine for COVID-19

Learn more
31. October 2019

The challenges of
translation

Commentary in EMBO Molecular Medicine

Learn more
17. July 2019

Making cancer stem cells visible for the immune system

Publication in Nature

Learn more

Research

The increasing understanding of the mechanisms underlying host-tumor interaction led to development of strategies that harness antitumor immunity for cancer treatment. However, while immunotherapy meanwhile has become a mainstay of tumor therapy, there is still ample room for improvement. Some patients do not respond to presently available approaches at all, others for limited time only, and for many cancer entities so far no immunotherapeutic strategies are available. In our view, this calls for efforts to more rapidly translate promising results from research to clinical application. To achieve this superordinate goal, our work focusses on the following key aspects:

Here we investigate the role of various immunoregulatory molecules involved in host-tumor interaction, in particular with putative tumor stem cells. Beyond improving the understanding of tumor biology per se, these studies aim to identify new target molecules for immunotherapeutic approaches and to identify prognostic markers for disease progression and response in patients. We further investigate how "conventional" systemic tumor therapeutics influence the immune response to enable rational combinations with immunotherapy. In addition, the development of valid model systems for testing novel strategies prior to application in humans is an important basis to develop rational immunotherapeutics.

The "preclinical" work mentioned above provides the basis for the second focus of our work, which is clearly focused on clinical application. This includes the development of optimized mono- and bispecific antibodies, novel immunocytokines and personalized peptide vaccination strategies. Our efforts cover the entire process, from conception and manufacture to clinical application in patients. This enables the rapid translation of results from basic research to novel therapies for cancer patients ("bench to bedside"). The feasibility of our approach is reflected by our various clinical studies with in-house developed  immunotherapeutics.

Clinical studies

Education and Career

Education

The rapid developments in tumor immunology and immunotherapy during the recent years call for a greater focus on this topic during academic education. Therefore, the CCU Translational Immunology participates in numerous classes and curricula in human medicine, biochemistry, biology and molecular medicine. In addition to strengthening basic immunological education, in our view it is particularly important to inspire students of human medicine for research for tumor immunology. Likewise it is equally important to illustrate the potential, but also the difficulties of translation in the field of immunotherapy to students of non-clinical natural sciences. Accordingly, we consider an early involvement of students and later also resident physicians and PhD students in translational research as a very important aspect of academic education. The various research groups within the CCU Translational Immunology offer the opportunity to gain insights into basic research and translational projects during internships, bachelor's and master's theses as well as medical and scientific doctoral dissertations. We provide numerous opportunities for further education within the framework of the iFIT excellence cluster, the National Center for Tumor Diseases (NCT) Southwest and by attending national and international meetings as well as workshops and courses for career development.

Career

The CCU Translational Immunology offers resident physicians and specialists of the various disciplines involved in treatment of cancer patients the opportunity to gain experience in the development and conduct of clinical trials within the scope of a rotation. With support of our experienced lab staff, this also provides a chance to conduct research projects with the aim to publish scientific work, which enables the application for internal and external research funds as well as research scholarships for stays abroad. For a rotation to the CCU Translational Immunology, a minimum of 2 years clinical experience is mandatory. 

Applications from motivated students for a position to conduct a master's thesis or a medical or scientific doctoral thesis are welcome. The same applies to Ph.D. scientists interested in our field.

Contact

Administrative office
Sabrina Augstein

+49 7071 29-83275

+49 7071 29-4391


E-mail address: Sabrina.augstein@med.uni-tuebingen.de


Certificates and Associations

Go to the main content
Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
 
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.

Zurück

Cookies zulassen Nur notwendige Cookies zulassen